Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Abiraterone Acetate,[H][C@@]12CC=C3C[C@H](CC[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=CC[C@@]21[H])C1=CN=CC=C1)OC(C)=O,Jaundice,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 202379/S-005 Part 02, page:24 PDF 11481k",https://www.pharmapendium.com/browse/fda/Abiraterone Acetate/9c3b3e563560fa0130081aaa6af9d8c4?reference=24,2012.0,[H][C]12CC=C3C[CH](CC[C]3(C)[C]1([H])CC[C]1(C)C(=CC[C]21[H])C1=CN=CC=C1)OC(C)=O
Acalabrutinib,CC#CC(=O)N1CCC[C@H]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N,Jaundice,Human,-2.0,Repeated,Oral,"EMA approval document: ANNEX I, page:39 PDF 288k",https://www.pharmapendium.com/browse/ema/Acalabrutinib/5e6c422fffed9e24fbcf6128dba2134c?reference=39,2020.0,CC#CC(=O)N1CCC[CH]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N
Acarbose,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 020482/S-001, S003, S004, S005, S006, S-009 Part 03, page:50 PDF 2583k",https://www.pharmapendium.com/browse/fda/Acarbose/266f462ff01cd4cf4b561b7a08b7a59d?reference=50,1995.0,C[CH]1O[CH](O[CH]2[CH](CO)O[CH](O[CH]3[CH](CO)OC(O)[CH](O)[CH]3O)[CH](O)[CH]2O)[CH](O)[CH](O)[CH]1N[CH]1C=C(CO)[CH](O)[CH](O)[CH]1O
Adefovir Dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Jaundice,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021449/S-000 Part 01, page:58 PDF 1882k",https://www.pharmapendium.com/browse/fda/Adefovir Dipivoxil/fd32899894085e0f71dd0ff92984a2fa?reference=58,,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
Agomelatine,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1,Jaundice,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:3 PDF 445k",https://www.pharmapendium.com/browse/ema/Agomelatine/8f1a8e32ead8fc917201fd71a0b5d214?reference=3,2020.0,COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1
Alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,Jaundice,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Printed Labeling 021726/S-000, page:16 PDF 1977k",https://www.pharmapendium.com/browse/fda/Alprazolam/1df31e0b37180d1cffaefc2ea15e6eca?reference=16,,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
Amifampridine,NC1=CC=NC=C1N,Jaundice,Human,-2.2430380486862944,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020932/S-000 Part 05, page:9 PDF 1500k",https://www.pharmapendium.com/browse/fda/Amifampridine/4ddaa96b28d6d1ece0eeb70141eba5a5?reference=9,2019.0,NC1=CC=NC=C1N
Aminosalicylic Acid,NC1=CC=C(C(O)=O)C(O)=C1,Jaundice,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 006924, page:4 PDF 675k",https://www.pharmapendium.com/browse/fda/Aminosalicylic Acid/0e570efeadba8d5ab058994c07b64375?reference=4,,NC1=CC=C(C(O)=O)C(O)=C1
Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Jaundice,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 018972/S-014 Part 18, page:4 PDF 5937k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/f61559ce465d19b11a15e17eb7a4e51c?reference=4,1983.0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Amlexanox,CC(C)C1=CC=C2OC3=NC(N)=C(C=C3C(=O)C2=C1)C(O)=O,Jaundice,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 020511/S-000, page:28 PDF 7022k",https://www.pharmapendium.com/browse/fda/Amlexanox/1476b403d08e8c472cac41c7c6f777c2?reference=28,1996.0,CC(C)C1=CC=C2OC3=NC(N)=C(C=C3C(=O)C2=C1)C(O)=O
Amphotericin B,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,Jaundice,Human,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Approval Package 050724 Part 04, page:6 PDF 4130k",https://www.pharmapendium.com/browse/fda/Amphotericin B/2d9ca1b6cf96fb8db3da224d7e9e499f?reference=6,1995.0,[H][C]12C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH](C)[CH](C)OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C](O)(C[CH](O)[CH]1C(O)=O)O2
Amphotericin B Liposome,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@H]1C)O2)C(O)=O,Jaundice,Human,0.0,Repeated,Intravenous,"FDA approval package document: Medical Officer Review 050740/S-000, page:18 PDF 1287k",https://www.pharmapendium.com/browse/fda/Amphotericin B Liposome/0c6d0fd13f3637cc249b301db5b08141?reference=18,1996.0,C[CH]1OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C]2(O)C[CH](O)[CH]([CH](C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH]1C)O2)C(O)=O
Anagrelide Hydrochloride,ClC1=C(Cl)C2=C(C=C1)N=C1NC(=O)CN1C2,Jaundice,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/697040/2014; EMEA/H/C/000480/II/0059, page:35 PDF 8474k",https://www.pharmapendium.com/browse/ema/Anagrelide Hydrochloride/59f5b04d51fa9c8949eee541b4b3f25b?reference=35,2014.0,ClC1=C(Cl)C2=C(C=C1)N=C1NC(=O)CN1C2
Apixaban,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/478338/2014; EMEA/H/C/002148/II/0014/G, page:82 PDF 2588k",https://www.pharmapendium.com/browse/ema/Apixaban/63204c7b176325279d63eef03f2d71ff?reference=82,2014.0,COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O
Argatroban,C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=C2NCC(C)CC2=CC=C1,Jaundice,Human,-2.6989700043360187,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020883/S-000 Part 02, page:16 PDF 1482k",https://www.pharmapendium.com/browse/fda/Argatroban/b122a5989d050ed712a3caf647e9286a?reference=16,2000.0,C[CH]1CCN([CH](C1)C(O)=O)C(=O)[CH](CCCNC(N)=N)NS(=O)(=O)C1=C2NCC(C)CC2=CC=C1
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Jaundice,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 021436/S-040 Part 01, page:46 PDF 404k",https://www.pharmapendium.com/browse/fda/Aripiprazole/a2af6e7da518a0cf49640b5e2fcbb513?reference=46,2016.0,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Artesunate,[H][C@@]12CC[C@@]3(C)OO[C@@]11[C@@]([H])(CC[C@H]2C)[C@@H](C)[C@@H](OC(=O)CCC(O)=O)O[C@]1([H])O3,Jaundice,Human,-0.6020599913279624,Repeated,Intravenous,"FDA approval package document: Label 213036/S-001, page:1 PDF 555k",https://www.pharmapendium.com/browse/fda/Artesunate/25eca5d1ff07104034b08c1687ae5066?reference=1,2020.0,[H][C]12CC[C]3(C)OO[C]11[C]([H])(CC[CH]2C)[CH](C)[CH](OC(=O)CCC(O)=O)O[C]1([H])O3
Atorvastatin Calcium,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,Jaundice,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020702/S-060 Part 02, page:7 PDF 1883k",https://www.pharmapendium.com/browse/fda/Atorvastatin Calcium/c157c681fd3f1d0d42787909373a77bf?reference=7,2012.0,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[CH](O)C[CH](O)CC([O-])=O)C1=CC=C(F)C=C1
Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1,Jaundice,Human,-1.6020599913279623,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/453325/2012; EMEA/H/C/002406, page:73 PDF 1208k",https://www.pharmapendium.com/browse/ema/Axitinib/755c1be86b9ebb59766d67a496ec4500?reference=73,2012.0,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1
Azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Jaundice,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 065488/S-002 Part 01, page:17 PDF 2508k",https://www.pharmapendium.com/browse/fda/Azithromycin/6dbfdbc999ef9120663ed3d70f42ef80?reference=17,2017.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(O)C[CH](C)CN(C)[CH](C)[CH](O)[C]1(C)O
Aztreonam,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O,Jaundice,Human,-3.4771212547196626,Repeated,Parenteral,"FDA approval package document: Approval Package 050580 Part 01, page:27 PDF 8962k",https://www.pharmapendium.com/browse/fda/Aztreonam/6c273762992adaf8c1f986d26d8f0572?reference=27,1986.0,C[CH]1[CH](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
Balsalazide Disodium,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O,Jaundice,Human,-4.8750612633917,Repeated,Oral,"FDA approval package document: Label 020610/S-014, page:8 PDF 337k",https://www.pharmapendium.com/browse/fda/Balsalazide Disodium/84390a507bff32ec4c79256e84a73323?reference=8,2006.0,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O
Benoxaprofen,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018250 Part 06, page:38 PDF 6047k",https://www.pharmapendium.com/browse/fda/Benoxaprofen/5312b25dcc6727268d88955af8b474b5?reference=38,1976.0,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1
Benzthiazide,NS(=O)(=O)C1=C(Cl)C=C2N=C(CSCC3=CC=CC=C3)NS(=O)(=O)C2=C1,Jaundice,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Review 012489, page:6 PDF 1758k",https://www.pharmapendium.com/browse/fda/Benzthiazide/a9eecdc78e4073e5f7451d3e2e0ca21b?reference=6,,NS(=O)(=O)C1=C(Cl)C=C2N=C(CSCC3=CC=CC=C3)NS(=O)(=O)C2=C1
Bialamicol Hydrochloride,CCN(CC)CC1=CC(=CC(CC=C)=C1O)C1=CC(CN(CC)CC)=C(O)C(CC=C)=C1,Jaundice,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 009303, page:4 PDF 491k",https://www.pharmapendium.com/browse/fda/Bialamicol Hydrochloride/4fc13a5a693b6dcbeb7cc63ccbb27cc7?reference=4,1967.0,CCN(CC)CC1=CC(=CC(CC=C)=C1O)C1=CC(CN(CC)CC)=C(O)C(CC=C)=C1
Bicalutamide,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical Officer Review 020498, page:2 PDF 255k",https://www.pharmapendium.com/browse/fda/Bicalutamide/27f03ce3355ae660a0da79fc9524871a?reference=2,1995.0,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F
Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,Jaundice,Human,-2.0969100130080562,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021290/S-001, page:28 PDF 891k",https://www.pharmapendium.com/browse/fda/Bosentan/018ecab3c97955ac0145961b8921fe86?reference=28,2003.0,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1
Budesonide,[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(CCC)O2)C(=O)CO,Jaundice,Human,-0.9542425094393249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021324/S-000 Part 03, page:25 PDF 1481k",https://www.pharmapendium.com/browse/fda/Budesonide/3b6153685c1503877971bfca05bd65b0?reference=25,2001.0,[H][C]12C[C]3([H])[C]4([H])CCC5=CC(=O)C=C[C]5(C)[C]4([H])[CH](O)C[C]3(C)[C]1(OC(CCC)O2)C(=O)CO
Buprenorphine Hydrochloride,[H][C@@]1(C[C@@]23CC[C@]1(OC)[C@@H]1OC4=C(O)C=CC5=C4[C@]21CCN(CC1CC1)[C@@H]3C5)[C@](C)(O)C(C)(C)C,Jaundice,Human,-1.2041199826559248,Repeated,Sublingual,"FDA approval package document: Medical/Clinical Review 204442/S-000 Part 06, page:137 PDF 22179k",https://www.pharmapendium.com/browse/fda/Buprenorphine Hydrochloride/f3b7b67010a881ad416f9c16b61b5110?reference=137,2013.0,[H][C]1(C[C]23CC[C]1(OC)[CH]1OC4=C(O)C=CC5=C4[C]21CCN(CC1CC1)[CH]3C5)[C](C)(O)C(C)(C)C
Bupropion Hydrochloride,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Review 077285/S-000, page:8 PDF 2859k",https://www.pharmapendium.com/browse/fda/Bupropion Hydrochloride/4670270ed4f0750f946dd93e73bbac0a?reference=8,2008.0,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1
Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,Jaundice,Human,-0.6020599913279624,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020954/S-000 Part 03, page:8 PDF 604k",https://www.pharmapendium.com/browse/fda/Busulfan/971fcbf2c5c41c97f835db4454ac3572?reference=8,1998.0,CS(=O)(=O)OCCCCOS(C)(=O)=O
Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,Jaundice,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 018343/S-013, S-005, S-018 Part 02, page:10 PDF 3959k",https://www.pharmapendium.com/browse/fda/Captopril/34babee9aef97c53c91b863fc75e8345?reference=10,1980.0,C[CH](CS)C(=O)N1CCC[CH]1C(O)=O
Carbimazole,CCOC(=O)N1C=CN(C)C1=S,Jaundice,Human,-1.6020599913279623,Repeated,Oral,Reference from PharmaPendium Published Toxicity: carbimazole9   ---   DOI:10.1371/journal.pmed.0030012   JOURNAL:PLoS Medicine   PAGES:e12   VOLUME:3,http://dx.doi.org/10.1371/journal.pmed.0030012,2006.0,CCOC(=O)N1C=CN(C)C1=S
Carglumic Acid,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,Jaundice,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022562/S-000, page:173 PDF 2464k",https://www.pharmapendium.com/browse/fda/Carglumic Acid/60be13855cb689641363df5de5fc093b?reference=173,2010.0,NC(=O)N[CH](CCC(O)=O)C(O)=O
Carteolol Hydrochloride,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2,Jaundice,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 019204 Part 01, page:2 PDF 5749k",https://www.pharmapendium.com/browse/fda/Carteolol Hydrochloride/7500040fe3a502b3c82f20206fa1b9cb?reference=2,1988.0,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2
Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Printed Labeling 050749/S-000, page:23 PDF 1493k",https://www.pharmapendium.com/browse/fda/Cefdinir/10c4f05e362d284ea2ef7800cb8bc9b3?reference=23,1997.0,[H][C]12SCC(C=C)=C(N1C(=O)[CH]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
Cefepime Hydrochloride,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1,Jaundice,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050679 Part 05, page:8 PDF 7286k",https://www.pharmapendium.com/browse/fda/Cefepime Hydrochloride/26dc9da0a13b65253a80cf6670386b15?reference=8,1996.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1
Cefixime,NC1=NC(=CS1)\C(=N\OCC(O)=O)C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 203195/S-000, page:8 PDF 342k",https://www.pharmapendium.com/browse/fda/Cefixime/5279558257d9d7022b458b599fd3b15e?reference=8,2012.0,NC1=NC(=CS1)\C(=N\OCC(O)=O)C(=O)N[CH]1[CH]2SCC(C=C)=C(N2C1=O)C(O)=O
Cefoxitin Sodium,CO[C@]1(NC(=O)CC2=CC=CS2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C([O-])=O,Jaundice,Human,-1.9030899869919435,Repeated,Parenteral,"FDA approval package document: Approval Package 050517 Part 02, page:10 PDF 3859k",https://www.pharmapendium.com/browse/fda/Cefoxitin Sodium/80873e0bd83c2880e5cdc03144c6bb13?reference=10,1978.0,CO[C]1(NC(=O)CC2=CC=CS2)[CH]2SCC(COC(N)=O)=C(N2C1=O)C([O-])=O
Ceftriaxone Sodium,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(CSC3=NC(=O)C(O)=NN3C)=C(N2C1=O)C([O-])=O)/C1=CSC(N)=N1,Jaundice,Human,-1.6020599913279623,Repeated,Parenteral,"FDA approval package document: Approval Package 050585 Part 06, page:48 PDF 7328k",https://www.pharmapendium.com/browse/fda/Ceftriaxone Sodium/12c252b83bc92a9fc2555e0e278fb2b2?reference=48,1984.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(CSC3=NC(=O)C(O)=NN3C)=C(N2C1=O)C([O-])=O)/C1=CSC(N)=N1
Cefuroxime Axetil,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)\C1=CC=CO1,Jaundice,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 050605 Part 07, page:28 PDF 5620k",https://www.pharmapendium.com/browse/fda/Cefuroxime Axetil/08328ccfe25099560f86ffc21580439d?reference=28,1985.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)\C1=CC=CO1
Celecoxib,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020998/S-010 Part 03, page:47 PDF 1486k",https://www.pharmapendium.com/browse/fda/Celecoxib/809da1d6e8ba492ce6bbf92c9e151491?reference=47,2000.0,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Jaundice,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Label 205755/S-000, page:4 PDF 588k",https://www.pharmapendium.com/browse/fda/Ceritinib/8fa0a723a811da4a973bf04603d3f3d9?reference=4,2014.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Cetirizine Hydrochloride,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical Officer Review 019835, page:74 PDF 2341k",https://www.pharmapendium.com/browse/fda/Cetirizine Hydrochloride/4cdb889601e30d90611b896193680b9d?reference=74,1994.0,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Chenodiol,[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])CC[C@]3(C)[C@]([H])(CC[C@@]3([H])[C@]1([H])[C@H](O)C2)[C@H](C)CCC(O)=O,Jaundice,Human,-0.9030899869919435,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Chenodiol   ---   DOI:10.2169/internalmedicine1962.26.404   JOURNAL:Japanese Journal of Medicine   PAGES:404   VOLUME:26,http://dx.doi.org/10.2169/internalmedicine1962.26.404,1987.0,[H][C]12C[CH](O)CC[C]1(C)[C]1([H])CC[C]3(C)[C]([H])(CC[C]3([H])[C]1([H])[CH](O)C2)[CH](C)CCC(O)=O
Chlorpromazine Hydrochloride,CN(C)CCCN1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2,Jaundice,Human,-0.47712125471966244,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Chlorpromazine0041a   ---   JOURNAL:British Medical Journal   PAGES:579   VOLUME:2,,1954.0,CN(C)CCCN1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2
Cholic acid,[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])C[C@H](O)[C@]3(C)[C@]([H])(CC[C@@]3([H])[C@]1([H])[C@H](O)C2)[C@H](C)CCC(O)=O,Jaundice,Human,-1.1760912590556813,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 546k",https://www.pharmapendium.com/browse/ema/Cholic acid/e276a741c2e1f90d8fb94ee88f89cc4d?reference=6,2020.0,[H][C]12C[CH](O)CC[C]1(C)[C]1([H])C[CH](O)[C]3(C)[C]([H])(CC[C]3([H])[C]1([H])[CH](O)C2)[CH](C)CCC(O)=O
Cinchophen,OC(=O)C1=C2C=CC=CC2=NC(=C1)C1=CC=CC=C1,Jaundice,Human,-3.9030899869919438,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Cinchophen21   ---   JOURNAL:California and Western Medicine   PAGES:269   VOLUME:35,,1931.0,OC(=O)C1=C2C=CC=CC2=NC(=C1)C1=CC=CC=C1
Ciprofloxacin Hydrochloride,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O,Jaundice,Human,-3.3010299956639813,Repeated,Intravenous,"FDA approval package document: Approval Package 020780/S-017, S-018; 019537/S-053, S-054, page:5 PDF 3215k",https://www.pharmapendium.com/browse/fda/Ciprofloxacin Hydrochloride/0e2c9703e8f743bf0652849a2b661fe1?reference=5,2004.0,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O
Cisapride Monohydrate,CO[C@@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC,Jaundice,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020210/S-000, page:88 PDF 7171k",https://www.pharmapendium.com/browse/fda/Cisapride Monohydrate/5928402f9fea4bc4c511c83a8d82225e?reference=88,1992.0,CO[CH]1CN(CCCOC2=CC=C(F)C=C2)CC[CH]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
Citalopram Hydrobromide,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Jaundice,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 021046/S-019; 020822/S-042 Part 02, page:25 PDF 436k",https://www.pharmapendium.com/browse/fda/Citalopram Hydrobromide/3a22838868d92f333fb8ee367eaef081?reference=25,2012.0,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Clofazimine,CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C/1NC1=CC=C(Cl)C=C1,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 019500/S-000, page:14 PDF 2175k",https://www.pharmapendium.com/browse/fda/Clofazimine/698747737f2e7d99da9cfa67f709a871?reference=14,1985.0,CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C/1NC1=CC=C(Cl)C=C1
Clomipramine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12,Jaundice,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 019906/S-001, S-005, S-007, S-013, S-014, S-015, S-016 Part 04, page:24 PDF 8193k",https://www.pharmapendium.com/browse/fda/Clomipramine Hydrochloride/fed7531165af624a91d49b5d740e4784?reference=24,1991.0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=C(Cl)C=C12
Clopidogrel Hydrobromide,COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl,Jaundice,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:36 PDF 770k",https://www.pharmapendium.com/browse/ema/Clopidogrel Hydrobromide/f4e3980f774689c09aa0d0a34c5849df?reference=36,2015.0,COC(=O)[CH](N1CCC2=C(C1)C=CS2)C1=CC=CC=C1Cl
Clotrimazole,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 076387/S-000, page:22 PDF 4831k",https://www.pharmapendium.com/browse/fda/Clotrimazole/cef0ccd841fd1322d55de96d8415658d?reference=22,2002.0,ClC1=C(C=CC=C1)C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,Jaundice,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Label 203479/S-000, page:27 PDF 1267k",https://www.pharmapendium.com/browse/fda/Clozapine/107c277867a1040822f8ad90fa780b3d?reference=27,2013.0,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2
Cobicistat,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203094/S-000 Part 05, page:74 PDF 15871k",https://www.pharmapendium.com/browse/fda/Cobicistat/cf97ec370dc39aa6baa9336ae252e4c6?reference=74,2012.0,CC(C)C1=NC(CN(C)C(=O)N[CH](CCN2CCOCC2)C(=O)N[CH](CC[CH](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
Colchicine,COC1=CC=C2C(=CC1=O)[C@H](CCC1=CC(OC)=C(OC)C(OC)=C21)NC(C)=O,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 210942/S-000 Part 03, page:7 PDF 463k",https://www.pharmapendium.com/browse/fda/Colchicine/2c46a6017a68ea06a7f07e23e3a3a4b6?reference=7,2018.0,COC1=CC=C2C(=CC1=O)[CH](CCC1=CC(OC)=C(OC)C(OC)=C21)NC(C)=O
Cyclobenzaprine Hydrochloride,CN(C)CC\C=C1\C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Jaundice,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021777/S-000, page:21 PDF 6375k",https://www.pharmapendium.com/browse/fda/Cyclobenzaprine Hydrochloride/d2cb881e69752f874659302be787c471?reference=21,2005.0,CN(C)CC\C=C1\C2=C(C=CC=C2)C=CC2=C1C=CC=C2
Cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,Jaundice,Human,-1.6989700043360187,Repeated,Oral,Reference from PharmaPendium Published Toxicity: cyclophosphamide-0078a   ---   JOURNAL:British Medical Journal   PAGES:588   VOLUME:3,,1970.0,ClCCN(CCCl)P1(=O)NCCCO1
Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,Jaundice,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 050715 Part 02, page:41 PDF 7730k",https://www.pharmapendium.com/browse/fda/Cyclosporine/e47cefdf0f7516975fa9b8f9aa8b7175?reference=41,1995.0,CC[CH]1NC(=O)[CH]([CH](O)[CH](C)C\C=C\C)N(C)C(=O)[CH](C(C)C)N(C)C(=O)[CH](CC(C)C)N(C)C(=O)[CH](CC(C)C)N(C)C(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CC(C)C)N(C)C(=O)[CH](NC(=O)[CH](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Cyproheptadine Hydrochloride,CN1CC\C(CC1)=C1/C2=CC=CC=C2C=CC2=CC=CC=C12,Jaundice,Human,-1.0791812460476249,Repeated,Oral,Reference from PharmaPendium Published Toxicity: cyproheptadine0021a   ---   JOURNAL:British Medical Journal   PAGES:753   VOLUME:1,,1978.0,CN1CC\C(CC1)=C1/C2=CC=CC=C2C=CC2=CC=CC=C12
Dalfampridine,NC1=CC=NC=C1,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022250/S-000 Part 02, page:75 PDF 1108k",https://www.pharmapendium.com/browse/fda/Dalfampridine/a5ede310e62e95cb9f9abfac156e0dbf?reference=75,2009.0,NC1=CC=NC=C1
Danazol,[H][C@@]12CCC3=CC4=C(C[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@@]1(O)C#C)C=NO4,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 017557/S-002, S-003, S-004, S-006 Part 02, page:44 PDF 4163k",https://www.pharmapendium.com/browse/fda/Danazol/97667b2cbb0a1bec203ef186413cc433?reference=44,1976.0,[H][C]12CCC3=CC4=C(C[C]3(C)[C]1([H])CC[C]1(C)[C]2([H])CC[C]1(O)C#C)C=NO4
Daptomycin,CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O,Jaundice,Human,-1.6812412373755872,Repeated,Intravenous,"FDA approval package document: Approval Package 021572/S-053 Part 01, page:16 PDF 973k",https://www.pharmapendium.com/browse/fda/Daptomycin/573e93f1d9a475c3db03f0f0c0a6f0aa?reference=16,2016.0,CCCCCCCCCC(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC(O)=O)C(=O)N[CH]1[CH](C)OC(=O)[CH](CC(=O)C2=C(N)C=CC=C2)NC(=O)[CH](NC(=O)[CH](CO)NC(=O)CNC(=O)[CH](CC(O)=O)NC(=O)[CH](C)NC(=O)[CH](CC(O)=O)NC(=O)[CH](CCCN)NC(=O)CNC1=O)[CH](C)CC(O)=O
Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Jaundice,Human,-3.0791812460476247,Repeated,Oral,"EMA approval document: Assessment Report EMEA/CHMP/632968/2008, page:21 PDF 378k",https://www.pharmapendium.com/browse/ema/Darunavir Ethanolate/492ebca4980ae8fa34e17e873b4be117?reference=21,2008.0,[H][C]12OCC[C]1([H])[CH](CO2)OC(=O)N[CH](CC1=CC=CC=C1)[CH](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021882/S-015, page:67 PDF 19012k",https://www.pharmapendium.com/browse/fda/Deferasirox/1bc5e6d94c09702cdc491a7390df0456?reference=67,2013.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Deferiprone,CN1C=CC(=O)C(O)=C1C,Jaundice,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Label 021825/S-000, page:5 PDF 480k",https://www.pharmapendium.com/browse/fda/Deferiprone/0234805df6e5bfb94e2a43e5b0274c2b?reference=5,2011.0,CN1C=CC(=O)C(O)=C1C
Desipramine Hydrochloride,CNCCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2,Jaundice,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Label 014399/S-063, page:9 PDF 321k",https://www.pharmapendium.com/browse/fda/Desipramine Hydrochloride/3ac94c9b28e9866d08159a62f2f03f88?reference=9,2006.0,CNCCCN1C2=C(CCC3=C1C=CC=C3)C=CC=C2
Desloratadine,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 184k",https://www.pharmapendium.com/browse/ema/Desloratadine/35facc8312dd7b99035a3008bdeaab6d?reference=4,2019.0,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1
Dextropropoxyphene,CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1,Jaundice,Human,-0.6989700043360189,Repeated,Oral,Reference from PharmaPendium Published Toxicity: dextropropoxyphene0106   ---   DOI:10.1136/gut.27.4.444   JOURNAL:Gut   PAGES:444   VOLUME:27,http://dx.doi.org/10.1136/gut.27.4.444,1986.0,CCC(=O)O[C](CC1=CC=CC=C1)([CH](C)CN(C)C)C1=CC=CC=C1
Diazepam,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C12,Jaundice,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 013263/S-003, S-008, S-019, S-040, S-041, S-042, S-043, S-046, S-049, S-054; 016087/S-040, S-042, S-045; 017984/S-010; 018179/S-001 Part 01, page:23 PDF 4467k",https://www.pharmapendium.com/browse/fda/Diazepam/c07af973f7b6af41e0a0b1e6c18fe979?reference=23,1963.0,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C12
Diclofenac,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Jaundice,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 204592/S-004 Part 02, page:7 PDF 449k",https://www.pharmapendium.com/browse/fda/Diclofenac/14e6f137ad4ea91951440d702014f0d7?reference=7,2014.0,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Diclofenac Potassium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 020142/S-001, S-002, S-004 Part 01, page:18 PDF 8395k",https://www.pharmapendium.com/browse/fda/Diclofenac Potassium/4b75f5a5589b3ba68ec8439b1369fb45?reference=18,1993.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Dirithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Jaundice,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 050678 Part 02, page:20 PDF 5481k",https://www.pharmapendium.com/browse/fda/Dirithromycin/a6c4fabc5a94a7b7f2c880d168e6a978?reference=20,1993.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(O)C[CH](C)[CH]2N[CH](COCCOC)O[CH]([CH]2C)[C]1(C)O
Disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,Jaundice,Human,-2.3010299956639813,Repeated,Oral,Reference from PharmaPendium Published Toxicity: disulfiram-0024   ---   JOURNAL:British Medical Journal   PAGES:94   VOLUME:2,,1977.0,CCN(CC)C(=S)SSC(=S)N(CC)CC
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Jaundice,Human,-1.6989700043360187,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/772068/2013; EMEA/H/C/002753/0000, page:82 PDF 1031k",https://www.pharmapendium.com/browse/ema/Dolutegravir Sodium/09d6171337e823a2f9a36399c3b91330?reference=82,2013.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Donepezil Hydrochloride,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1,Jaundice,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 020690/S-011, page:5 PDF 1420k",https://www.pharmapendium.com/browse/fda/Donepezil Hydrochloride/ef2ae315038913ac33f9a72dc8b8e642?reference=5,2003.0,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1
Doripenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Jaundice,Human,-2.6989700043360187,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/594074/2014; EMEA/H/000891/P46/030, page:14 PDF 1202k",https://www.pharmapendium.com/browse/ema/Doripenem/12f2a00b81318441b7b1c88fec60490b?reference=14,2014.0,[H][C]12[CH](C)C(S[CH]3CN[CH](CNS(N)(=O)=O)C3)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Doxepin Hydrochloride,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=CC=C12,Jaundice,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Label 022036/S-000, page:13 PDF 462k",https://www.pharmapendium.com/browse/fda/Doxepin Hydrochloride/63f1ba282c95744b407a45389e65d3a1?reference=13,2010.0,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=CC=C12
Dronedarone Hydrochloride,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,Jaundice,Human,-2.9030899869919438,Repeated,Intramuscular,"EMA approval document: Assessment Report EMEA/H/C/1043/A20/005, page:18 PDF 943k",https://www.pharmapendium.com/browse/ema/Dronedarone Hydrochloride/ac8f06b056b2958a2f0f1a402458ce78?reference=18,2011.0,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12
Duloxetine Hydrochloride,CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1,Jaundice,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: Procedural Steps EMA/491981/2020, page:30 PDF 375k",https://www.pharmapendium.com/browse/ema/Duloxetine Hydrochloride/278e42f82bd11c495500ea83a3872921?reference=30,2020.0,CNCC[CH](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1
Dydrogesterone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@@]12C,Jaundice,Human,-1.1760912590556813,Repeated,Oral,Reference from PharmaPendium Published Toxicity: dydrogesterone314   ---   JOURNAL:Turkish Journal of Gastroenterology   PAGES:49   VOLUME:15,,2004.0,[H][C]12CC[CH](C(C)=O)[C]1(C)CC[C]1([H])[C]2([H])C=CC2=CC(=O)CC[C]12C
Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:22 PDF 861k",https://www.pharmapendium.com/browse/ema/Efavirenz/096c26d9f63461f688969abc7108c6b3?reference=22,2019.0,FC(F)(F)[C]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Jaundice,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 204629/S-001, S-002, S-003 Part 02, page:20 PDF 4874k",https://www.pharmapendium.com/browse/fda/Empagliflozin/d9389650199146fc07985b7833daf787?reference=20,2015.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Encainide,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 018981/S-001 Part 10, page:45 PDF 4788k",https://www.pharmapendium.com/browse/fda/Encainide/6cba4c684b45d059c4be622543f67c56?reference=45,1989.0,COC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1C
Epoprostenol Sodium,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC([O-])=O,Jaundice,Human,-7.681241237375588,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020444/S-003 Part 01, page:19 PDF 1223k",https://www.pharmapendium.com/browse/fda/Epoprostenol Sodium/e45112e315c6961c805c3f17ed128c8c?reference=19,1999.0,CCCCC[CH](O)\C=C\[CH]1[CH](O)C[CH]2O\C(C[CH]12)=C/CCCC([O-])=O
Ertapenem Sodium,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C([O-])=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Jaundice,Human,-3.0,Repeated,Parenteral,"FDA approval package document: Medical/Clinical Review 021337/S-000 Part 08, page:4 PDF 2239k",https://www.pharmapendium.com/browse/fda/Ertapenem Sodium/cc72dce592eca1fde335ab3568876ad2?reference=4,2001.0,[H][C]12[CH](C)C(S[CH]3CN[CH](C3)C(=O)NC3=CC(=CC=C3)C([O-])=O)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Jaundice,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 050536 Part 02, page:30 PDF 5214k",https://www.pharmapendium.com/browse/fda/Erythromycin/ab80ecb6ee983e9b863a967e38ee73e2?reference=30,1979.0,CC[CH]1OC(=O)[CH](C)[CH](O[CH]2C[C](C)(OC)[CH](O)[CH](C)O2)[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2O)N(C)C)[C](C)(O)C[CH](C)C(=O)[CH](C)[CH](O)[C]1(C)O
Erythromycin Ethylsuccinate,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2OC(=O)CCC(=O)OCC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C,Jaundice,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 006205/S-034 Part 03, page:6 PDF 364k",https://www.pharmapendium.com/browse/fda/Erythromycin Ethylsuccinate/bdf04bcb268ada18ca166a2d0fb1d20c?reference=6,2018.0,[H][C]1(C[C](C)(OC)[CH](O)[CH](C)O1)O[CH]1[CH](C)[CH](O[C]2([H])O[CH](C)C[CH]([CH]2OC(=O)CCC(=O)OCC)N(C)C)[C](C)(O)C[CH](C)C(=O)[CH](C)[CH](O)[C](C)(O)[CH](CC)OC(=O)[CH]1C
Esomeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)[S@@](=O)CC1=NC=C(C)C(OC)=C1C,Jaundice,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 022101/S-000, page:8 PDF 1747k",https://www.pharmapendium.com/browse/fda/Esomeprazole Magnesium/db2013fb81f87cc67d86cb99ff99b37c?reference=8,2008.0,COC1=CC=C2[N-]C(=NC2=C1)[S](=O)CC1=NC=C(C)C(OC)=C1C
Estradiol,[H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])CCC1=C2C=CC(O)=C1,Jaundice,Human,-2.574031267727719,Repeated,Skin,"FDA approval package document: Approval Package 020538 020323 Part 02, page:66 PDF 3668k",https://www.pharmapendium.com/browse/fda/Estradiol/f54572bda05f5248c6376cb8b0121c3e?reference=66,1996.0,[H][C]12CC[C]3(C)[CH](O)CC[C]3([H])[C]1([H])CCC1=C2C=CC(O)=C1
Ethacrynic Acid,CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl,Jaundice,Human,-1.6989700043360187,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Ethacrynic Acid-0048   ---   JOURNAL:British Medical Journal   PAGES:152   VOLUME:3,,1967.0,CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O,Jaundice,Human,-1.2041199826559248,Repeated,Oral,"FDA approval package document: Approval Package 018922/S-007, S-008, S-013, S-014, S-015 Part 06, page:35 PDF 4880k",https://www.pharmapendium.com/browse/fda/Etodolac/c688b5771656ff786492cf1489a4c479?reference=35,1991.0,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
Etravirine,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N,Jaundice,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022187/S-000 Part 02, page:31 PDF 6254k",https://www.pharmapendium.com/browse/fda/Etravirine/23cba3104661ccebce18224813c53489?reference=31,2008.0,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
Ezogabine,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,Jaundice,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022345/S-000 Part 09, page:13 PDF 798k",https://www.pharmapendium.com/browse/fda/Ezogabine/32ffc5ac0f220009d9a5886e136f3359?reference=13,2011.0,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
Famciclovir,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O,Jaundice,Human,-3.1760912590556813,Repeated,Oral,"FDA approval package document: Label 020363/S-026, page:11 PDF 399k",https://www.pharmapendium.com/browse/fda/Famciclovir/0a65f49eab88e6edbd20187a778111ca?reference=11,2006.0,CC(=O)OCC(CCN1C=NC2=C1N=C(N)N=C2)COC(C)=O
Febuxostat,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:8 PDF 300k",https://www.pharmapendium.com/browse/ema/Febuxostat/9263bc582cfb24cf942ce6af88777fab?reference=8,2019.0,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O
Fenoprofen Calcium,CC(C([O-])=O)C1=CC=CC(OC2=CC=CC=C2)=C1,Jaundice,Human,-3.2041199826559246,Repeated,Oral,"FDA approval package document: Approval Package 017710; 017604/S-018, page:26 PDF 2632k",https://www.pharmapendium.com/browse/fda/Fenoprofen Calcium/bc12048541c8f2bf0029ac4ce060b3da?reference=26,1977.0,CC(C([O-])=O)C1=CC=CC(OC2=CC=CC=C2)=C1
Fentanyl,CCC(=O)N(C1CCN(CC1)CCC1=CC=CC=C1)C1=CC=CC=C1,Jaundice,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Label 021947/S-000, page:20 PDF 5478k",https://www.pharmapendium.com/browse/fda/Fentanyl/9f82dca1717332f7c79d0c01ef2eb7e7?reference=20,2006.0,CCC(=O)N(C1CCN(CC1)CCC1=CC=CC=C1)C1=CC=CC=C1
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Jaundice,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 11, page:33 PDF 876k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/d7059e44b20a49f9940c212d18b49443?reference=33,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Jaundice,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022527/S-000 Part 08, page:48 PDF 1113k",https://www.pharmapendium.com/browse/fda/Fingolimod Hydrochloride/972ed03239ccc918de6c168481c7e6ec?reference=48,2009.0,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Flucytosine,NC1=NC(=O)NC=C1F,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Label 017001/S-000, page:5 PDF 1236k",https://www.pharmapendium.com/browse/fda/Flucytosine/8b4c46f692806fc09b1eedcba617a43e?reference=5,2009.0,NC1=NC(=O)NC=C1F
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Jaundice,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020187 Part 01, page:26 PDF 8906k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/0d183d7c2ae1a5db56e9486f8922c8b5?reference=26,1994.0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Flurazepam Hydrochloride,CCN(CC)CCN1C(=O)CN=C(C2=CC=CC=C2F)C2=CC(Cl)=CC=C12,Jaundice,Human,-0.7781512503836436,Repeated,Oral,Reference from PharmaPendium Published Toxicity: flurazepam hydrochloride-0065   ---   JOURNAL:Canadian Family Physician   PAGES:893   VOLUME:124,,1981.0,CCN(CC)CCN1C(=O)CN=C(C2=CC=CC=C2F)C2=CC(Cl)=CC=C12
Flurbiprofen,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Label 018766/S-013, page:7 PDF 339k",https://www.pharmapendium.com/browse/fda/Flurbiprofen/42077615ee502ab6ea0ace4341e5e783?reference=7,2006.0,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
Fluticasone Propionate,[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Jaundice,Human,-3.0,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 208798/S-000, page:138 PDF 18534k",https://www.pharmapendium.com/browse/fda/Fluticasone Propionate/e0d19891639bb6dbe0eb33be98b0b680?reference=138,2016.0,[H][C]12C[CH](C)[C](OC(=O)CC)(C(=O)SCF)[C]1(C)C[CH](O)[C]1(F)[C]2([H])C[CH](F)C2=CC(=O)C=C[C]12C
Fluvastatin Sodium,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,Jaundice,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 021192/S-019 Part 05, page:2 PDF 521k",https://www.pharmapendium.com/browse/fda/Fluvastatin Sodium/be8b5afab2b747166667c0f95a6e0704?reference=2,2012.0,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[CH](O)C[CH](O)CC([O-])=O
Gabapentin,NCC1(CCCCC1)CC(O)=O,Jaundice,Human,-3.255272505103306,Repeated,Oral,"FDA approval package document: Label 022544/S-000, page:8 PDF 334k",https://www.pharmapendium.com/browse/fda/Gabapentin/761deb8eb7a3c6983c2018f70aaddc94?reference=8,2011.0,NCC1(CCCCC1)CC(O)=O
Ganciclovir,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,Jaundice,Human,-1.0,Repeated,Intravenous,"FDA approval package document: Approval Package 020460/S-005 Part 01, page:40 PDF 5337k",https://www.pharmapendium.com/browse/fda/Ganciclovir/af8b89aafda27afd4ca3e4f3b3ba71ff?reference=40,1994.0,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
Glimepiride,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,Jaundice,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 076802/S-000 Part 01, page:16 PDF 4059k",https://www.pharmapendium.com/browse/fda/Glimepiride/ee930d2eb23075b11a9bad21106e07b4?reference=16,2005.0,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[CH]2CC[CH](C)CC2)C1=O
Hydromorphone Hydrochloride,[H][C@]12CCC(=O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4O,Jaundice,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Printed Labeling 021044/S-000, page:19 PDF 1633k",https://www.pharmapendium.com/browse/fda/Hydromorphone Hydrochloride/e205dd35bf555afc3333e8974a0838fb?reference=19,2004.0,[H][C]12CCC(=O)[CH]3OC4=C5C(C[CH]1N(C)CC[C]235)=CC=C4O
Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,Jaundice,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 020418 Part 01, page:43 PDF 5445k",https://www.pharmapendium.com/browse/fda/Ibuprofen/4768e9343291bb3125cc346a426033be?reference=43,1994.0,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Imipramine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Label 087846/S-026, page:2 PDF 283k",https://www.pharmapendium.com/browse/fda/Imipramine Hydrochloride/407c55c284989deef12a3767134016d1?reference=2,2013.0,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12
Indomethacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,Jaundice,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Label 204768/S-000, page:10 PDF 513k",https://www.pharmapendium.com/browse/fda/Indomethacin/8739319fb80bf8712b81706fd68b8752?reference=10,2014.0,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 1238k",https://www.pharmapendium.com/browse/ema/Irbesartan/b7fb1f5d5cfcf95dc2a7a3c8fdc4e102?reference=7,2017.0,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Jaundice,Human,-2.6020599913279625,Repeated,Oral/intravenous,"FDA approval package document: Medical/Clinical Review 020657/S-004, S-005; 020966/S-001, S-003, S-004 Part 03, page:7 PDF 1737k",https://www.pharmapendium.com/browse/fda/Itraconazole/3ac61938995410475e27f19d0e006ddd?reference=7,2000.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,Jaundice,Human,-3.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:16 PDF 553k",https://www.pharmapendium.com/browse/ema/Ketoconazole/8d2315e4697688e9c94ee9b957e597c1?reference=16,2020.0,[H][C]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical Officer Review 020429 Part 02, page:25 PDF 1711k",https://www.pharmapendium.com/browse/fda/Ketoprofen/294fff90244c022796a65f8836bc24b2?reference=25,1995.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Labetalol Hydrochloride,CC(CCC1=CC=CC=C1)NCC(O)C1=CC=C(O)C(=C1)C(N)=O,Jaundice,Human,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Approval Package 018687/S-002, S-005, S-008; 018686/S-005, S-006 Part 02, page:60 PDF 4737k",https://www.pharmapendium.com/browse/fda/Labetalol Hydrochloride/d2aee4cc6683343a8bfb0e0757f634df?reference=60,1989.0,CC(CCC1=CC=CC=C1)NCC(O)C1=CC=C(O)C(=C1)C(N)=O
Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022253/S-000; 022254/S-000 Part 03, page:92 PDF 6885k",https://www.pharmapendium.com/browse/fda/Lacosamide/e8591abb7cc398480feaf4f98f1b54e2?reference=92,2008.0,COC[CH](NC(C)=O)C(=O)NCC1=CC=CC=C1
Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021003/S-000; 021004/S-000 Part 02, page:9 PDF 1190k",https://www.pharmapendium.com/browse/fda/Lamivudine/7c6e1619f95c9fc2e29616fe111898a9?reference=9,1998.0,NC1=NC(=O)N(C=C1)[CH]1CS[CH](CO)O1
Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,Jaundice,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020406 Part 03, page:56 PDF 4102k",https://www.pharmapendium.com/browse/fda/Lansoprazole/09618525313fa9c4e0aeb7c47359985f?reference=56,1995.0,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Lasofoxifene,OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 474k",https://www.pharmapendium.com/browse/ema/Lasofoxifene/4a30d26487d86d298e55209f18660544?reference=7,2013.0,OC1=CC=C2[CH]([CH](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:12 PDF 479k",https://www.pharmapendium.com/browse/ema/Leflunomide/143ff05cfedd6e28c7e1a3db69e310f5?reference=12,2018.0,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Jaundice,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: ANNEX I, page:94 PDF 639k",https://www.pharmapendium.com/browse/ema/Lenalidomide/25cd756533c94cddbdd01735140f5be1?reference=94,2021.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Levocetirizine Dihydrochloride,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209089/S-000 Part 05, page:1 PDF 6557k",https://www.pharmapendium.com/browse/fda/Levocetirizine Dihydrochloride/948fdb30f4ff12481b10470f1e10197d?reference=1,2016.0,OC(=O)COCCN1CCN(CC1)[CH](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Jaundice,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020634, page:31 PDF 1138k",https://www.pharmapendium.com/browse/fda/Levofloxacin/8d76cd44935db74bf226896c315f58c7?reference=31,1998.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Levonorgestrel,[H][C@]12CCC(=O)C=C1CC[C@]1([H])[C@]2([H])CC[C@@]2(CC)[C@@]1([H])CC[C@@]2(O)C#C,Jaundice,Human,-1.9294189257142926,Repeated,Implant,"FDA approval package document: Approval Package 019897/S-001, S-002, S-003, S-004 Part 03, page:16 PDF 2964k",https://www.pharmapendium.com/browse/fda/Levonorgestrel/9dd6d78e0245b565e53aaefabca754d2?reference=16,1990.0,[H][C]12CCC(=O)C=C1CC[C]1([H])[C]2([H])CC[C]2(CC)[C]1([H])CC[C]2(O)C#C
Linagliptin,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201280/S-000 Part 04, page:98 PDF 5485k",https://www.pharmapendium.com/browse/fda/Linagliptin/4040600348d5f8e24c3f5c858638a448?reference=98,2010.0,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[CH](N)C1
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Jaundice,Human,-0.47712125471966244,Repeated,Subcutaneous,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 206321/S-000 Part 03, page:39 PDF 4929k",https://www.pharmapendium.com/browse/fda/Liraglutide/89607ebb61bab857867a252b0f96e5b3?reference=39,2014.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Loperamide Hydrochloride,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1,Jaundice,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019487/S-007 Part 02, page:44 PDF 6802k",https://www.pharmapendium.com/browse/fda/Loperamide Hydrochloride/37dbb74fd531640da4b651274266df32?reference=44,1988.0,CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1
Loracarbef,[H][C@]12CCC(Cl)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,Jaundice,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 050667 Part 12, page:21 PDF 7287k",https://www.pharmapendium.com/browse/fda/Loracarbef/a412eef245a776e8971eb9879e8a0da1?reference=21,1991.0,[H][C]12CCC(Cl)=C(N1C(=O)[CH]2NC(=O)[CH](N)C1=CC=CC=C1)C(O)=O
Loratadine,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,Jaundice,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021512/S-000, page:52 PDF 5129k",https://www.pharmapendium.com/browse/fda/Loratadine/689b662fc01741a2528c703f19e17543?reference=52,2004.0,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2
Lorlatinib,C[C@H]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210868/S-000 Part 09, page:57 PDF 1228k",https://www.pharmapendium.com/browse/fda/Lorlatinib/bd3ecb44dfc93ea65ade6b9e1d3ea355?reference=57,2018.0,C[CH]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
Loxapine Hydrochloride,CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Label 017525/S-051; 017658/S-038; 018039/S-024, page:6 PDF 325k",https://www.pharmapendium.com/browse/fda/Loxapine Hydrochloride/5891388147ae5ecbac6dabcb4b794667?reference=6,2017.0,CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2
Macitentan,CCCNS(=O)(=O)NC1=C(C2=CC=C(Br)C=C2)C(OCCOC2=NC=C(Br)C=N2)=NC=N1,Jaundice,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 204410/S-000, page:4 PDF 1037k",https://www.pharmapendium.com/browse/fda/Macitentan/e45922be3091f9f6b63a1a09d3103ffa?reference=4,2013.0,CCCNS(=O)(=O)NC1=C(C2=CC=C(Br)C=C2)C(OCCOC2=NC=C(Br)C=N2)=NC=N1
Mebhydrolin,CN1CCC2=C(C1)C1=C(C=CC=C1)N2CC1=CC=CC=C1,Jaundice,Human,-1.6989700043360187,Repeated,Unreported,Reference from PharmaPendium Published Toxicity: #19   ---   DOI:10.1111/j.1365-2230.1993.tb00993.x   JOURNAL:Clinical and Experimental Dermatology   PAGES:131   VOLUME:18,http://dx.doi.org/10.1111/j.1365-2230.1993.tb00993.x,1993.0,CN1CCC2=C(C1)C1=C(C=CC=C1)N2CC1=CC=CC=C1
Mebutamate,CCC(C)C(C)(COC(N)=O)COC(N)=O,Jaundice,Human,-1.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Mebutamate0034   ---   JOURNAL:Canadian Medical Association Journal   PAGES:993   VOLUME:89,,1963.0,CCC(C)C(C)(COC(N)=O)COC(N)=O
Mefenamic Acid,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1,Jaundice,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 015034/S-032, page:8 PDF 827k",https://www.pharmapendium.com/browse/fda/Mefenamic Acid/bcd696f706f5701412ad5bbb95fb4620?reference=8,1998.0,CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O,Jaundice,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Correspondence 020938, page:65 PDF 2240k",https://www.pharmapendium.com/browse/fda/Meloxicam/557f0598b8abb1ca7b9189d325f39fcd?reference=65,1998.0,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=CC=CC=C2S1(=O)=O
Memantine Hydrochloride,[H][C@]12C[C@]3(C)C[C@](C)(C1)C[C@](N)(C2)C3,Jaundice,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021487/S-000 Part 04, page:40 PDF 1517k",https://www.pharmapendium.com/browse/fda/Memantine Hydrochloride/232901fe8089434495f89a3a69af53b3?reference=40,2003.0,[H][C]12C[C]3(C)C[C](C)(C1)C[C](N)(C2)C3
Mepazine,CN1CCCC(C1)CN1C2=C(SC3=C1C=CC=C3)C=CC=C2,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Review 010559, page:4 PDF 1365k",https://www.pharmapendium.com/browse/fda/Mepazine/5005c2ea90be09c57f70c7c3e3a97ae3?reference=4,,CN1CCCC(C1)CN1C2=C(SC3=C1C=CC=C3)C=CC=C2
Mercaptopurine,S=C1NC=NC2=C1NC=N2,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 205919/S-000, page:4 PDF 1266k",https://www.pharmapendium.com/browse/fda/Mercaptopurine/c434c89bc8f0dc47ad8a93b7dfc72c7c?reference=4,2014.0,S=C1NC=NC2=C1NC=N2
Meropenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Jaundice,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Approval Package 050706/S-034, page:15 PDF 842k",https://www.pharmapendium.com/browse/fda/Meropenem/92831c508d9b53c9444030ab8cb98ee9?reference=15,2013.0,[H][C]12[CH](C)C(S[CH]3CN[CH](C3)C(=O)N(C)C)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Mesalamine,NC1=CC(C(O)=O)=C(O)C=C1,Jaundice,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 020049/S-027, page:14 PDF 2721k",https://www.pharmapendium.com/browse/fda/Mesalamine/40d98ac615806c2b81bf36d919f134ee?reference=14,2015.0,NC1=CC(C(O)=O)=C(O)C=C1
Metaxalone,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1,Jaundice,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Label 022503/S-000, page:4 PDF 726k",https://www.pharmapendium.com/browse/fda/Metaxalone/6aaa9924c4062ac48dee8cd105239495?reference=4,2015.0,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1
Metformin Hydrochloride,CN(C)C(=N)NC(N)=N,Jaundice,Human,-2.929418925714293,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020357 Part 03, page:8 PDF 1951k",https://www.pharmapendium.com/browse/fda/Metformin Hydrochloride/031d8bc21f6a622b853c27a3ef611e56?reference=8,,CN(C)C(=N)NC(N)=N
Methandrostenolone,[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(C)O,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 087945, page:8 PDF 5345k",https://www.pharmapendium.com/browse/fda/Methandrostenolone/16203c757fbeb7542443861859af3c88?reference=8,1990.0,[H][C]12CCC3=CC(=O)C=C[C]3(C)[C]1([H])CC[C]1(C)[C]2([H])CC[C]1(C)O
Methimazole,CN1C=CNC1=S,Jaundice,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Label 007517/S-022, page:3 PDF 480k",https://www.pharmapendium.com/browse/fda/Methimazole/d0109b41ed065fe52623158b8c92a5d5?reference=3,2009.0,CN1C=CNC1=S
Methyclothiazide,CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O,Jaundice,Human,-1.0,Repeated,Oral,"FDA approval package document: Review 012524, page:5 PDF 978k",https://www.pharmapendium.com/browse/fda/Methyclothiazide/23b50569fead1ed788b7c97b770f5137?reference=5,,CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O
Methyldopa,C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O,Jaundice,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 018934, page:35 PDF 4491k",https://www.pharmapendium.com/browse/fda/Methyldopa/fa30339d523adb3e6fe776628b5625c7?reference=35,1984.0,C[C](N)(CC1=CC(O)=C(O)C=C1)C(O)=O
Methyltestosterone,[H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(C)O,Jaundice,Human,-1.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Methyltestosterone-0023   ---   JOURNAL:British Medical Journal   PAGES:259   VOLUME:1,,1959.0,[H][C]12CCC3=CC(=O)CC[C]3(C)[C]1([H])CC[C]1(C)[C]2([H])CC[C]1(C)O
Metoclopramide Hydrochloride,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,Jaundice,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 071402/S-007 Part 01, page:18 PDF 488k",https://www.pharmapendium.com/browse/fda/Metoclopramide Hydrochloride/0702fbf29ca5ed4fabf5f5402a227616?reference=18,2009.0,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Jaundice,Human,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021506/S-015 Part 09, page:14 PDF 1371k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/b59ea7e20ea58b45b6dc1acb021a1b7d?reference=14,2012.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Midostaurin,[H][C@]12C[C@H]([C@@H](OC)[C@](C)(O1)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1,Jaundice,Human,-1.6989700043360187,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/516229/2017; EMEA/H/C/004095/0000, page:181 PDF 7394k",https://www.pharmapendium.com/browse/ema/Midostaurin/7ca7a1ea535abba143f839369c00f2d4?reference=181,2017.0,[H][C]12C[CH]([CH](OC)[C](C)(O1)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1
Miltefosine,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204684/S-000 Part 01, page:12 PDF 685k",https://www.pharmapendium.com/browse/fda/Miltefosine/d578768c04ada62a2f887e64d74423fb?reference=12,2014.0,CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C
Minocycline Hydrochloride,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Jaundice,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050808/S-000, page:101 PDF 8349k",https://www.pharmapendium.com/browse/fda/Minocycline Hydrochloride/d6acfaee627320264b8bbd095cd3d77b?reference=101,2005.0,[H][C]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2
Molindone Hydrochloride,CCC1=C(C)NC2=C1C(=O)C(CC2)CN1CCOCC1,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 017111/S-048, S-049, S-050 Part 01, page:10 PDF 5683k",https://www.pharmapendium.com/browse/fda/Molindone Hydrochloride/2b905c58b158336bb554e7538dc4d5db?reference=10,1974.0,CCC1=C(C)NC2=C1C(=O)C(CC2)CN1CCOCC1
Monoctanoin,CCCCCCCC(=O)OCC(O)CO,Jaundice,Human,-1.0,Repeated,Parenteral,"FDA approval package document: Approval Package 019368/S-001, S-002 Part 01, page:37 PDF 3790k",https://www.pharmapendium.com/browse/fda/Monoctanoin/103031764c0e06310a7f9d7011ab1653?reference=37,1985.0,CCCCCCCC(=O)OCC(O)CO
Moricizine Hydrochloride,CCOC(=O)NC1=CC=C2SC3=C(C=CC=C3)N(C(=O)CCN3CCOCC3)C2=C1,Jaundice,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Approval Package 019753 Part 01, page:20 PDF 6242k",https://www.pharmapendium.com/browse/fda/Moricizine Hydrochloride/c3f0b79bd6f99d950b0cee99b32b827b?reference=20,1990.0,CCOC(=O)NC1=CC=C2SC3=C(C=CC=C3)N(C(=O)CCN3CCOCC3)C2=C1
Moxifloxacin Hydrochloride,[H][C@@]12CCCN[C@]1([H])CN(C2)C1=C(OC)C2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O,Jaundice,Human,-0.7781512503836436,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021085/S-061; 021277/S-057 Part 02, page:13 PDF 435k",https://www.pharmapendium.com/browse/fda/Moxifloxacin Hydrochloride/57b5a0bc69de3088593f4933e17c69a3?reference=13,2016.0,[H][C]12CCCN[C]1([H])CN(C2)C1=C(OC)C2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O
Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1,Jaundice,Human,-3.4771212547196626,Repeated,Intravenous,"EMA approval document: ANNEX I, page:32 PDF 1007k",https://www.pharmapendium.com/browse/ema/Mycophenolate Mofetil/98df93bfd743b8a911ebd23509e3398a?reference=32,2020.0,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
Naproxen,COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(O)=O,Jaundice,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 020067 Part 01, page:18 PDF 8319k",https://www.pharmapendium.com/browse/fda/Naproxen/7342328e88aeda028c75243aeb46ee4f?reference=18,1994.0,COC1=CC2=CC=C(C=C2C=C1)[CH](C)C(O)=O
Naproxen Sodium,COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C([O-])=O,Jaundice,Human,-3.041392685158225,Repeated,Oral,"FDA approval package document: Approval Package 018164/S-033 Part 01, page:30 PDF 4353k",https://www.pharmapendium.com/browse/fda/Naproxen Sodium/0af36fb04083fc9cfb242f50b3bec539?reference=30,1978.0,COC1=CC2=CC=C(C=C2C=C1)[CH](C)C([O-])=O
Nateglinide,CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](CC1=CC=CC=C1)C(O)=O,Jaundice,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021204/S-000 Part 01, page:14 PDF 1952k",https://www.pharmapendium.com/browse/fda/Nateglinide/55e4dc4aff7091a8fe16427174a95a83?reference=14,2000.0,CC(C)[CH]1CC[CH](CC1)C(=O)N[CH](CC1=CC=CC=C1)C(O)=O
Nebivolol Hydrochloride,[H][C@@]1(CCC2=CC(F)=CC=C2O1)[C@H](O)CNC[C@@H](O)[C@]1([H])CCC2=CC(F)=CC=C2O1,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021742/S-000 Part 09, page:35 PDF 5918k",https://www.pharmapendium.com/browse/fda/Nebivolol Hydrochloride/2fdc64943782b19a8a6fa822c35b20c8?reference=35,2007.0,[H][C]1(CCC2=CC(F)=CC=C2O1)[CH](O)CNC[CH](O)[C]1([H])CCC2=CC(F)=CC=C2O1
Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: ANNEX I, page:17 PDF 742k",https://www.pharmapendium.com/browse/ema/Nevirapine/f3292fccf515eca05ba0b31687fcd313?reference=17,2020.0,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1
Niacin,OC(=O)C1=CC=CN=C1,Jaundice,Human,-4.845098040014257,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Aluminum0075   ---   JOURNAL:California Medicine   PAGES:267   VOLUME:96,,1962.0,OC(=O)C1=CC=CN=C1
Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC,Jaundice,Human,-1.954242509439325,Repeated,Oral,"FDA approval package document: Approval Package 077410/S-000 Part 01, page:18 PDF 8529k",https://www.pharmapendium.com/browse/fda/Nifedipine/fd1fd8c55b113ef9c9793784895e6f15?reference=18,2007.0,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1N(=O)=O)C(=O)OC
Nilotinib Hydrochloride Monohydrate,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 022068/S-000, page:10 PDF 326k",https://www.pharmapendium.com/browse/fda/Nilotinib Hydrochloride Monohydrate/f322685b508d762bb135f8a217a6a292?reference=10,2007.0,CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)C=C2)=C1)C(F)(F)F
Nilutamide,CC1(C)NC(=O)N(C2=CC=C(C(=C2)C(F)(F)F)N(=O)=O)C1=O,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical Officer Review 020169, page:14 PDF 591k",https://www.pharmapendium.com/browse/fda/Nilutamide/fc6a923cc670cfaa1045fa4ebf0f27f4?reference=14,1995.0,CC1(C)NC(=O)N(C2=CC=C(C(=C2)C(F)(F)F)N(=O)=O)C1=O
Nimesulide,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)N(=O)=O,Jaundice,Human,-2.3010299956639813,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Nimesulidecr11   ---   JOURNAL:Singapore Medical Journal   PAGES:582   VOLUME:48,,2007.0,CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)N(=O)=O
Nimodipine,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OC(C)C,Jaundice,Human,-2.5563025007672873,Repeated,Oral,"FDA approval package document: Approval Package 018869/S-005, S-001 Part 05, page:42 PDF 9661k",https://www.pharmapendium.com/browse/fda/Nimodipine/9edfc9729e468aa4554d07f6f78d5b72?reference=42,1988.0,COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OC(C)C
Nitric Oxide,[N]=O,Jaundice,Human,-0.6989700043360189,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 020845 Part 03, page:8 PDF 558k",https://www.pharmapendium.com/browse/fda/Nitric Oxide/c65841d5b22edb8d1880eb48cbf0ee9f?reference=8,2010.0,[N]=O
"Nitrofurantoin, Macrocrystalline",O=C1CN(C(=O)N1)\N=C\C1=CC=C(O1)N(=O)=O,Jaundice,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 016620/S-064, page:29 PDF 2554k","https://www.pharmapendium.com/browse/fda/Nitrofurantoin, Macrocrystalline/87b6846f59ea68c204bf40dd016affea?reference=29",2003.0,O=C1CN(C(=O)N1)\N=C\C1=CC=C(O1)N(=O)=O
Nizatidine,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Printed Labeling 021494/S-000, page:8 PDF 972k",https://www.pharmapendium.com/browse/fda/Nizatidine/48bb51b3c36a8fa9cb390213dfb5f04b?reference=8,2004.0,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O
Nomifensine,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 018224 Part 02, page:36 PDF 3804k",https://www.pharmapendium.com/browse/fda/Nomifensine/e446c3328772dca77a06d98942f108c6?reference=36,1984.0,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2
Norethandrolone,[H][C@]12CCC(=O)C=C1CC[C@]1([H])[C@]2([H])CC[C@@]2(C)[C@@]1([H])CC[C@@]2(O)CC,Jaundice,Human,-1.6020599913279623,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Norethandrolone-0087   ---   JOURNAL:Canadian Medical Association Journal   PAGES:546   VOLUME:83,,1960.0,[H][C]12CCC(=O)C=C1CC[C]1([H])[C]2([H])CC[C]2(C)[C]1([H])CC[C]2(O)CC
Norethindrone,[H][C@]12CCC(=O)C=C1CC[C@]1([H])[C@]2([H])CC[C@@]2(C)[C@@]1([H])CC[C@@]2(O)C#C,Jaundice,Human,-0.6989700043360189,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Norethindrone-0041   ---   JOURNAL:British Medical Journal   PAGES:281   VOLUME:2,,1968.0,[H][C]12CCC(=O)C=C1CC[C]1([H])[C]2([H])CC[C]2(C)[C]1([H])CC[C]2(O)C#C
Norfloxacin,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1,Jaundice,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 019757/S-001, S-003, S-002, S-006 Part 06, page:4 PDF 1496k",https://www.pharmapendium.com/browse/fda/Norfloxacin/08b165de31f4ce5b7756b1f6a1b4eb34?reference=4,1991.0,CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(C=C12)N1CCNCC1
Nortriptyline Hydrochloride,CNCC\C=C1/C2=CC=CC=C2CCC2=CC=CC=C12,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 018012/S-024, page:13 PDF 989k",https://www.pharmapendium.com/browse/fda/Nortriptyline Hydrochloride/7a657806f0dd6653e06eb81774032c77?reference=13,2001.0,CNCC\C=C1/C2=CC=CC=C2CCC2=CC=CC=C12
Novobiocin Calcium,CO[C@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C([O-])=C(NC(=O)C2=CC=C(O)C(C\C=C(/C)C)=C2)C(=O)O3)OC1(C)C,Jaundice,Human,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 060693, page:10 PDF 1512k",https://www.pharmapendium.com/browse/fda/Novobiocin Calcium/6d55b2c4d4a72d6deda87995cef11f64?reference=10,1969.0,CO[CH]1[CH](OC(N)=O)[CH](O)[CH](OC2=C(C)C3=C(C=C2)C([O-])=C(NC(=O)C2=CC=C(O)C(C\C=C(/C)C)=C2)C(=O)O3)OC1(C)C
Novobiocin Sodium,CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](OC2=C(C)C3=C(C=C2)C([O-])=C(NC(=O)C2=CC=C(O)C(C\C=C(\C)C)=C2)C(=O)O3)OC1(C)C,Jaundice,Human,-3.0,Repeated,Oral,"FDA approval package document: Review 010307, page:4 PDF 2603k",https://www.pharmapendium.com/browse/fda/Novobiocin Sodium/eb662eb5ed16df5d2d42ce0af0829e13?reference=4,1969.0,CO[CH]1[CH](OC(N)=O)[CH](O)[CH](OC2=C(C)C3=C(C=C2)C([O-])=C(NC(=O)C2=CC=C(O)C(C\C=C(\C)C)=C2)C(=O)O3)OC1(C)C
Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Jaundice,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207999/S-000 Part 02, page:94 PDF 18088k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/af00f33f42b347c2e4d3d2cf294c81b5?reference=94,2016.0,[H][C]1(CC[C]2([H])[C]3([H])[CH](O)[CH](CC)[C]4([H])C[CH](O)CC[C]4(C)[C]3([H])CC[C]12C)[CH](C)CCC(O)=O
Ofloxacin,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 019735/S-052, page:31 PDF 2341k",https://www.pharmapendium.com/browse/fda/Ofloxacin/8ca463a478cff3d02544be358fb903cd?reference=31,2004.0,CC1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Label 020592/S-040, S-041, page:24 PDF 524k",https://www.pharmapendium.com/browse/fda/Olanzapine/123fdf978c5c8f8e5346b56d8750ede2?reference=24,2009.0,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Olaparib,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/789139/2014; EMEA/H/C/003726/0000, page:167 PDF 3649k",https://www.pharmapendium.com/browse/ema/Olaparib/4a8bb43cae260418da7bc88978d36d6d?reference=167,2014.0,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
Olopatadine Hydrochloride,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=C(CC(O)=O)C=C12,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021861/S-000 Part 01, page:68 PDF 1704k",https://www.pharmapendium.com/browse/fda/Olopatadine Hydrochloride/9eb9dbed0818da3a35597e43417acc9f?reference=68,2006.0,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=C(CC(O)=O)C=C12
Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022032/S-000, page:92 PDF 6854k",https://www.pharmapendium.com/browse/fda/Omeprazole/f6b25703d5175f3e9cf24629ad788b65?reference=92,2006.0,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Omeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Jaundice,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021229/S-000, page:86 PDF 20401k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/42ffe48b5d32d8a231f5c085c007aa78?reference=86,2003.0,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Jaundice,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021887/S-000 Part 01, page:43 PDF 4480k",https://www.pharmapendium.com/browse/fda/Orlistat/3f97e8190e694a8cb2e2e90a1f1afa61?reference=43,2005.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Oxaprozin,OC(=O)CCC1=NC(C2=CC=CC=C2)=C(O1)C1=CC=CC=C1,Jaundice,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 018841/S-003, S-001, S-002, S-004, S-005 Part 04, page:91 PDF 8811k",https://www.pharmapendium.com/browse/fda/Oxaprozin/f8c11882dbc89c2901ec12adf7a58359?reference=91,1992.0,OC(=O)CCC1=NC(C2=CC=CC=C2)=C(O1)C1=CC=CC=C1
Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12,Jaundice,Human,-3.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021014/S-000 Part 06, page:8 PDF 1647k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/44b120c1ccabb76ebd73a0eb1292f6c2?reference=8,1999.0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12
Oxyphenbutazone,CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1,Jaundice,Human,-2.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Oxyphenbutazone-0057a   ---   JOURNAL:British Medical Journal   PAGES:1517   VOLUME:2,,1962.0,CCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
Ozanimod Hydrochloride,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N,Jaundice,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209899/S-000 Part 04, page:27 PDF 9758k",https://www.pharmapendium.com/browse/fda/Ozanimod Hydrochloride/8b224be2239d5e5f42efec391f71668d?reference=27,2019.0,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[CH](NCCO)C2=CC=C1)C#N
Paliperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C(=O)N2CCCC(O)C2=N1,Jaundice,Human,-1.0791812460476249,Repeated,Oral,"EMA approval document: ANNEX I, page:11 PDF 283k",https://www.pharmapendium.com/browse/ema/Paliperidone/7832e622d98f35869ef7357b5b85a327?reference=11,2018.0,CC1=C(CCN2CCC(CC2)C2=NOC3=CC(F)=CC=C23)C(=O)N2CCCC(O)C2=N1
Paliperidone Palmitate,CCCCCCCCCCCCCCCC(=O)O[C@@H]1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=CC(F)=CC=C34)=C(C)N=C12,Jaundice,Human,-1.8750612633917,Repeated,Intramuscular,"EMA approval document: ANNEX I, page:32 PDF 528k",https://www.pharmapendium.com/browse/ema/Paliperidone Palmitate/4945c9953b218d971366d3a467544b2c?reference=32,2020.0,CCCCCCCCCCCCCCCC(=O)O[CH]1CCCN2C(=O)C(CCN3CCC(CC3)C3=NOC4=CC(F)=CC=C34)=C(C)N=C12
Pantoprazole Sodium,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,Jaundice,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020987/S-007, page:37 PDF 1373k",https://www.pharmapendium.com/browse/fda/Pantoprazole Sodium/fc792609ea1639d725d409fa83f0f250?reference=37,2002.0,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1
Papaverine Hydrochloride,COC1=CC=C(CC2=C3C=C(OC)C(OC)=CC3=CC=N2)C=C1OC,Jaundice,Human,-2.7781512503836434,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Papaverine -0033   ---   DOI:10.1136/pgmj.56.657.488   JOURNAL:Postgraduate Medical Journal   PAGES:488   VOLUME:56,http://dx.doi.org/10.1136/pgmj.56.657.488,1980.0,COC1=CC=C(CC2=C3C=C(OC)C(OC)=CC3=CC=N2)C=C1OC
Para-Aminosalicylic Sodium,NC1=CC(O)=C(C=C1)C([O-])=O,Jaundice,Human,-4.176091259055681,Repeated,Oral,"FDA approval package document: Approval Package 006924, page:2 PDF 466k",https://www.pharmapendium.com/browse/fda/Para-Aminosalicylic Sodium/7397980b824866d114c2314b7ec27352?reference=2,1967.0,NC1=CC(O)=C(C=C1)C([O-])=O
Paroxetine Hydrochloride,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,Jaundice,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 077873/S-000 Part 03, page:1 PDF 412k",https://www.pharmapendium.com/browse/fda/Paroxetine Hydrochloride/a509e558c60afc1d47a8429b40106097?reference=1,2007.0,FC1=CC=C(C=C1)[CH]1CCNC[CH]1COC1=CC=C2OCOC2=C1
Pazopanib Hydrochloride,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1,Jaundice,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022465/S-000, page:77 PDF 1560k",https://www.pharmapendium.com/browse/fda/Pazopanib Hydrochloride/893f6f8879191ff31ae434f60b8e4e98?reference=77,2009.0,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1
Phenindione,O=C1C(C(=O)C2=C1C=CC=C2)C1=CC=CC=C1,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 008700, page:5 PDF 3149k",https://www.pharmapendium.com/browse/fda/Phenindione/1384e35efd59dc9416e176680e27f5b4?reference=5,1966.0,O=C1C(C(=O)C2=C1C=CC=C2)C1=CC=CC=C1
Phenylbutazone,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1,Jaundice,Human,-1.1760912590556813,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Phenylbutazone0043   ---   JOURNAL:British Medical Journal   PAGES:795   VOLUME:2,,1965.0,CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 008762/S-039 Part 01, page:12 PDF 427k",https://www.pharmapendium.com/browse/fda/Phenytoin/f663eb919dfb8c88d5bfb73c9391cea1?reference=12,2011.0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
Pitavastatin Calcium,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O,Jaundice,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 022363/S-008, S-009 Part 04, page:9 PDF 3444k",https://www.pharmapendium.com/browse/fda/Pitavastatin Calcium/3c20e7bcb4408f4d275378e7739b930a?reference=9,2012.0,O[CH](C[CH](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O
Plicamycin,[H][C@]1(CC2=C(C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]3C[C@@H](O[C@H]4C[C@](C)(O)[C@H](O)[C@@H](C)O4)[C@@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O1)C(O)=C1C(C=C(O[C@H]3C[C@@H](O[C@H]4C[C@@H](O)[C@H](O)[C@@H](C)O4)[C@H](O)[C@@H](C)O3)C(C)=C1O)=C2)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O,Jaundice,Human,-4.3979400086720375,Repeated,Intravenous,"FDA approval package document: Approval Package 050109, page:29 PDF 3822k",https://www.pharmapendium.com/browse/fda/Plicamycin/748a11d0e6faeebe54a8496c631bd687?reference=29,1969.0,[H][C]1(CC2=C(C(=O)[CH]1O[CH]1C[CH](O[CH]3C[CH](O[CH]4C[C](C)(O)[CH](O)[CH](C)O4)[CH](O)[CH](C)O3)[CH](O)[CH](C)O1)C(O)=C1C(C=C(O[CH]3C[CH](O[CH]4C[CH](O)[CH](O)[CH](C)O4)[CH](O)[CH](C)O3)C(C)=C1O)=C2)[CH](OC)C(=O)[CH](O)[CH](C)O
Ponatinib Hydrochloride,CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F,Jaundice,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/220290/2013; EMEA/H/C/002695/0000, page:75 PDF 3061k",https://www.pharmapendium.com/browse/ema/Ponatinib Hydrochloride/fe3b348c74e83ea10cdb1f8b671495b8?reference=75,2013.0,CN1CCN(CC1)CC1=C(C=C(NC(=O)C2=CC(C#CC3=CN=C4C=CC=NN34)=C(C)C=C2)C=C1)C(F)(F)F
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: Scientific Discussion EMEA/H/C/611/II/01, page:17 PDF 466k",https://www.pharmapendium.com/browse/ema/Posaconazole/116c36add91b7a8b2c931855bc8dce36?reference=17,2006.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pramipexole Dihydrochloride,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,Jaundice,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022514/S-000 Part 15, page:2 PDF 472k",https://www.pharmapendium.com/browse/fda/Pramipexole Dihydrochloride/575ae229cbcdb9c8e44d2ea636ec39ce?reference=2,2009.0,CCCN[CH]1CCC2=C(C1)SC(N)=N2
Pravastatin Sodium,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC([O-])=O)OC(=O)[C@@H](C)CC,Jaundice,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-062 Part 01, page:16 PDF 1214k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/9cd2ea8d0b260d57f67d92089d7b101f?reference=16,2012.0,[H][C]12[CH](C[CH](O)C=C1C=C[CH](C)[CH]2CC[CH](O)C[CH](O)CC([O-])=O)OC(=O)[CH](C)CC
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:9 PDF 364k",https://www.pharmapendium.com/browse/ema/Pregabalin/f40a48444d7e1ea2aeff94fbc60f086d?reference=9,2021.0,CC(C)C[CH](CN)CC(O)=O
Pretomanid,FC(F)(F)OC1=CC=C(CO[C@@H]2COC3=NC(=CN3C2)N(=O)=O)C=C1,Jaundice,Human,-2.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:8 PDF 306k",https://www.pharmapendium.com/browse/ema/Pretomanid/b1f2d25a3bc79a74ac5a0f45b4aaffc4?reference=8,2021.0,FC(F)(F)OC1=CC=C(CO[CH]2COC3=NC(=CN3C2)N(=O)=O)C=C1
Promethazine Hydrochloride,CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C,Jaundice,Human,-1.6989700043360187,Repeated,Intramuscular,"FDA approval package document: Approval Package 040454/S-006, page:12 PDF 1775k",https://www.pharmapendium.com/browse/fda/Promethazine Hydrochloride/fb2fd43d86292d6c210aee70364601b2?reference=12,2011.0,CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C
Protriptyline Hydrochloride,CNCCCC1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Jaundice,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Label 073644/S-023; 073645/S-028, page:1 PDF 250k",https://www.pharmapendium.com/browse/fda/Protriptyline Hydrochloride/58d609709725a90acb8fde5cdacf1b9b?reference=1,2014.0,CNCCCC1C2=C(C=CC=C2)C=CC2=C1C=CC=C2
Pyritinol,CC1=C(O)C(CO)=C(CSSCC2=C(CO)C(O)=C(C)N=C2)C=N1,Jaundice,Human,-0.0,Repeated,Unreported,Reference from PharmaPendium Published Toxicity: Pyritinol32800572   ---   DOI:10.1136/bmj.328.7439.572   JOURNAL:British Medical Journal   PAGES:572   VOLUME:328,http://dx.doi.org/10.1136/bmj.328.7439.572,2004.0,CC1=C(O)C(CO)=C(CSSCC2=C(CO)C(O)=C(C)N=C2)C=N1
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020973/S-009 Part 02, page:87 PDF 14721k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/6b3f55d6bf0ad42f82ef4ae04d59ca5e?reference=87,2002.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Raltegravir Potassium,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022145/S-000 Part 01, page:80 PDF 6696k",https://www.pharmapendium.com/browse/fda/Raltegravir Potassium/af40780e21e1a3c69e5027a0fcf4730c?reference=80,2007.0,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Ramipril,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019901/S-013, S-014, S-008, S-009, S-010, S-014, S-011 Part 07, page:27 PDF 4417k",https://www.pharmapendium.com/browse/fda/Ramipril/e15409fe26a1e475e548c5e735da86aa?reference=27,1991.0,[H][C]12CCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Ranitidine Hydrochloride,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019675/S-012, S-013, S-016; 018703/S-046, S-050, S-019, S-042, S-047 Part 08, page:94 PDF 9533k",https://www.pharmapendium.com/browse/fda/Ranitidine Hydrochloride/611752294370761886d2e59319974880?reference=94,1994.0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Jaundice,Human,-2.2041199826559246,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/403683/2013; EMEA/H/C/002573/0000, page:71 PDF 1666k",https://www.pharmapendium.com/browse/ema/Regorafenib/38a3e8573c561839e7d1330db89c998e?reference=71,2013.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1,Jaundice,Human,-2.3010299956639813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 214787/S-000 Part 03, page:29 PDF 1237k",https://www.pharmapendium.com/browse/fda/Remdesivir/27efae85ef2e8d3460cff7dde5014c8d?reference=29,2020.0,CCC(CC)COC(=O)[CH](C)N[P](=O)(OC[CH]1O[C](C#N)([CH](O)[CH]1O)C1=CC=C2N1N=CN=C2N)OC1=CC=CC=C1
Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Jaundice,Human,-3.146128035678238,Repeated,Oral,"EMA approval document: ANNEX I, page:12 PDF 831k",https://www.pharmapendium.com/browse/ema/Ribavirin/5f3d429ef85eca746a2b1385496d70be?reference=12,2019.0,NC(=O)C1=NN(C=N1)[CH]1O[CH](CO)[CH](O)[CH]1O
Rifampin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(C)CC1)=C2O,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 064150/S-000 Part 02, page:8 PDF 897k",https://www.pharmapendium.com/browse/fda/Rifampin/4931d0b5312b80441b5f6d14519ce41d?reference=8,1997.0,CO[CH]1\C=C\O[C]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[CH](C)[CH](O)[CH](C)[CH](O)[CH](C)[CH](OC(C)=O)[CH]1C)C(\C=N\N1CCN(C)CC1)=C2O
Rifaximin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C1=C2N=C2C=C(C)C=CN12,Jaundice,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022554/S-000 Part 06, page:3 PDF 543k",https://www.pharmapendium.com/browse/fda/Rifaximin/42ecf6c4ada064088a22065b3a8ffcc2?reference=3,2009.0,CO[CH]1\C=C\O[C]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[CH](C)[CH](O)[CH](C)[CH](O)[CH](C)[CH](OC(C)=O)[CH]1C)C1=C2N=C2C=C(C)C=CN12
Riluzole,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1,Jaundice,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 020599/S-011 Part 02, page:10 PDF 901k",https://www.pharmapendium.com/browse/fda/Riluzole/415fe6a1fe1466cb3e9f679804930861?reference=10,2006.0,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
Ripretinib,CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 213973/S-000 Part 03, page:87 PDF 1501k",https://www.pharmapendium.com/browse/fda/Ripretinib/941c7fcb65a259e5e355595d65cfd141?reference=87,2020.0,CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Jaundice,Human,-1.6989700043360187,Repeated,Intramuscular,"FDA approval package document: Label 021346/S-013, page:28 PDF 1117k",https://www.pharmapendium.com/browse/fda/Risperidone/0c7946c7391b69ddee75d111e62bc4b5?reference=28,2006.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Ritodrine Hydrochloride,C[C@@H](NCCC1=CC=C(O)C=C1)[C@@H](O)C1=CC=C(O)C=C1,Jaundice,Human,-1.5440680443502757,Repeated,Intravenous,"FDA approval package document: Approval Package 018280 Part 01, page:27 PDF 4348k",https://www.pharmapendium.com/browse/fda/Ritodrine Hydrochloride/88751729a782c299361dadb6305c8b31?reference=27,1980.0,C[CH](NCCC1=CC=C(O)C=C1)[CH](O)C1=CC=C(O)C=C1
Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Label 020945/S-026; 020659/S-047, page:15 PDF 2773k",https://www.pharmapendium.com/browse/fda/Ritonavir/4b27276f9cf53709b84d1feb2499dfa0?reference=15,2009.0,CC(C)[CH](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[CH](C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Jaundice,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:60 PDF 1522k",https://www.pharmapendium.com/browse/ema/Rivaroxaban/f7df462dd06876f288288ba9d48e87d0?reference=60,2020.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,Jaundice,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021042, page:12 PDF 836k",https://www.pharmapendium.com/browse/fda/Rofecoxib/0b87368a9385b0585bd0fd32d7d2d03a?reference=12,,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
Rosuvastatin Calcium,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,Jaundice,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 021366/S-024 Part 01, page:16 PDF 980k",https://www.pharmapendium.com/browse/fda/Rosuvastatin Calcium/2cd0485f9c6ce0b1ebd43dfa3b6b9856?reference=16,2012.0,CC(C)C1=C(\C=C\[CH](O)C[CH](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
Rotigotine,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1,Jaundice,Human,-1.255272505103306,Repeated,Skin,"FDA approval package document: Medical/Clinical Review 021829/S-000 Part 01, page:73 PDF 5789k",https://www.pharmapendium.com/browse/fda/Rotigotine/949d8bfd5daf7f41d44eae2206bef307?reference=73,2006.0,CCCN(CCC1=CC=CS1)[CH]1CCC2=C(O)C=CC=C2C1
Ruboxistaurin,CN(C)C[C@@H]1CCN2C=C(C3=C2C=CC=C3)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=C2C=CC=C1,Jaundice,Human,-1.505149978319906,Repeated,Oral,"EMA approval document: Withdrawal Public Statement EMEA/150964/2007, page:38 PDF 552k",https://www.pharmapendium.com/browse/ema/Ruboxistaurin/80e3fd2450b28d7005fd6f11ddca4cfb?reference=38,2007.0,CN(C)C[CH]1CCN2C=C(C3=C2C=CC=C3)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=C2C=CC=C1
Silodosin,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=C(OCC(F)(F)F)C=CC=C1,Jaundice,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022206/S-000 Part 02, page:3 PDF 5777k",https://www.pharmapendium.com/browse/fda/Silodosin/4c97fbb5603e0a37c43dc9b7ac0fe9b7?reference=3,2007.0,C[CH](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=C(OCC(F)(F)F)C=CC=C1
Simeprevir Sodium,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1,Jaundice,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205123/S-000 Part 11, page:12 PDF 2371k",https://www.pharmapendium.com/browse/fda/Simeprevir Sodium/edcc84fc86e3aa2b7352c0d0b89a028d?reference=12,2013.0,[H][C]12C[C]1(NC(=O)[C]1([H])C[CH](C[C]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1
Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,Jaundice,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 019766/S-083 Part 01, page:17 PDF 385k",https://www.pharmapendium.com/browse/fda/Simvastatin/73a722d2b7c515509e5da806a439177c?reference=17,2011.0,[H][C]12[CH](C[CH](C)C=C1C=C[CH](C)[CH]2CC[CH]1C[CH](O)CC(=O)O1)OC(=O)C(C)(C)CC
Stanozolol,[H][C@@]12CC[C@]3([H])[C@]([H])(CC[C@@]4(C)[C@@]3([H])CC[C@]4(C)O)[C@@]1(C)CC1=C(C2)NN=C1,Jaundice,Human,-0.8450980400142568,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Stanozolol-0050   ---   DOI:10.1136/pgmj.52.606.229   JOURNAL:Postgraduate Medical Journal   PAGES:229   VOLUME:52,http://dx.doi.org/10.1136/pgmj.52.606.229,1976.0,[H][C]12CC[C]3([H])[C]([H])(CC[C]4(C)[C]3([H])CC[C]4(C)O)[C]1(C)CC1=C(C2)NN=C1
Stavudine,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,Jaundice,Human,-1.6020599913279623,Repeated,Oral,"EMA approval document: ANNEX I, page:9 PDF 3068k",https://www.pharmapendium.com/browse/ema/Stavudine/6ad9975c57fd1d005f31eb302771e254?reference=9,2020.0,CC1=CN([CH]2O[CH](CO)C=C2)C(=O)NC1=O
Sulfachlorpyridazine,NC1=CC=C(C=C1)S(=O)(=O)NC1=NN=C(Cl)C=C1,Jaundice,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Review 013141, page:10 PDF 1981k",https://www.pharmapendium.com/browse/fda/Sulfachlorpyridazine/6ea98de303f3a6a41b4f6a5f0cef65fa?reference=10,1962.0,NC1=CC=C(C=C1)S(=O)(=O)NC1=NN=C(Cl)C=C1
Sulfadiazine,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1,Jaundice,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 004125, page:10 PDF 705k",https://www.pharmapendium.com/browse/fda/Sulfadiazine/d3279cda9542a324ac653c0700ced40c?reference=10,1941.0,NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1
Sulfadiazine Sodium,NC1=CC=C(C=C1)S([O-])(=O)=NC1=NC=CC=N1,Jaundice,Human,0.0,Repeated,Oral/intravenous,"FDA approval package document: Approval Package 005036, page:9 PDF 601k",https://www.pharmapendium.com/browse/fda/Sulfadiazine Sodium/31e99bf0899d32958bd1027a7d20227a?reference=9,1942.0,NC1=CC=C(C=C1)S([O-])(=O)=NC1=NC=CC=N1
Sulfadimethoxine,COC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(OC)=N1,Jaundice,Human,-3.6989700043360187,Repeated,Oral,"FDA approval package document: Review 011766 Part 04, page:43 PDF 3798k",https://www.pharmapendium.com/browse/fda/Sulfadimethoxine/79dbf5f89784f6e41014a03dfa15f547?reference=43,1968.0,COC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(OC)=N1
Sulfaethidole,CCC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1,Jaundice,Human,-4.977723605288848,Repeated,Oral,"FDA approval package document: Review 010643, page:5 PDF 890k",https://www.pharmapendium.com/browse/fda/Sulfaethidole/c3b0ac9ec6a84bc2e372c0413dd1ffea?reference=5,,CCC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1
Sulfamerazine,CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1,Jaundice,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 005349, page:9 PDF 676k",https://www.pharmapendium.com/browse/fda/Sulfamerazine/a348103e3ed0215b2fc1b3ef59273df4?reference=9,1943.0,CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1
Sulfasalazine,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,Jaundice,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Label 021243/S-000, page:9 PDF 874k",https://www.pharmapendium.com/browse/fda/Sulfasalazine/cf8a0c6ad016a2a507078cca2fee3df1?reference=9,2000.0,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
Sulfisomidine,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(C)=N1,Jaundice,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 008070, page:9 PDF 911k",https://www.pharmapendium.com/browse/fda/Sulfisomidine/a19d0696d685c9a64af3b1407adac890?reference=9,,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(C)=N1
Sulfisoxazole,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C,Jaundice,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 006911, page:9 PDF 800k",https://www.pharmapendium.com/browse/fda/Sulfisoxazole/09c5a2029e65778acab805cdec5848fb?reference=9,,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
Sulfoxone Sodium,[O-]S(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS([O-])=O)C=C1,Jaundice,Human,-2.5185139398778875,Repeated,Oral,"FDA approval package document: Approval Package 006044, page:4 PDF 574k",https://www.pharmapendium.com/browse/fda/Sulfoxone Sodium/1da236c6d83b0a7a1f9144c8f2b66108?reference=4,1946.0,[O-]S(=O)CNC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(NCS([O-])=O)C=C1
Suprofen,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1,Jaundice,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 018217/S-011, S-009 Part 01, page:10 PDF 4960k",https://www.pharmapendium.com/browse/fda/Suprofen/0a0149b345a61a588da0aae3056d78c0?reference=10,1985.0,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Jaundice,Human,-1.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 01, page:64 PDF 10320k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/bccf76edc873f241b1898b3994cb3b19?reference=64,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Jaundice,Human,-1.2304489213782739,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206406/S-000 Part 02, page:8 PDF 654k",https://www.pharmapendium.com/browse/fda/Tacrolimus/c30840afd922a7b9861d9e52eb63613c?reference=8,2014.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Telithromycin,[H][C@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1,Jaundice,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 021144/S-012, page:16 PDF 657k",https://www.pharmapendium.com/browse/fda/Telithromycin/3525544120b4529175fd8596ec3552c0?reference=16,2007.0,[H][C]12[CH](C)C(=O)[CH](C)C[C](C)(OC)[CH](O[CH]3O[CH](C)C[CH]([CH]3O)N(C)C)[CH](C)C(=O)[CH](C)C(=O)O[CH](CC)[C]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Jaundice,Human,-1.146128035678238,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:13 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=13,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Thioguanine,NC1=NC2=C(NC=N2)C(=S)N1,Jaundice,Human,-1.6020599913279623,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Thioguanine-0131   ---   DOI:10.1136/gut.29.9.1265   JOURNAL:Gut   PAGES:1265   VOLUME:29,http://dx.doi.org/10.1136/gut.29.9.1265,1988.0,NC1=NC2=C(NC=N2)C(=S)N1
Thiotepa,S=P(N1CC1)(N1CC1)N1CC1,Jaundice,Human,-0.3010299956639812,Repeated,Intravenous,"EMA approval document: Assessment Report EMEA/H/C/001046, page:53 PDF 672k",https://www.pharmapendium.com/browse/ema/Thiotepa/c1684ffe2ec2ab818791ab1cdf48fbea?reference=53,2009.0,S=P(N1CC1)(N1CC1)N1CC1
Ticagrelor,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1,Jaundice,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/581260/2018; EMEA/H/C/001241/P46/023, page:28 PDF 1655k",https://www.pharmapendium.com/browse/ema/Ticagrelor/57f7e39744100070867d83a0e0416c13?reference=28,2018.0,CCCSC1=NC(N[CH]2C[CH]2C2=CC=C(F)C(F)=C2)=C2N=NN([CH]3C[CH](OCCO)[CH](O)[CH]3O)C2=N1
Tigecycline,[H][C@@]12CC3=C(C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C,Jaundice,Human,-2.0,Repeated,Intravenous,"EMA approval document: ANNEX I, page:8 PDF 222k",https://www.pharmapendium.com/browse/ema/Tigecycline/fcbe7feafd5e5510970a7557e0825006?reference=8,2020.0,[H][C]12CC3=C(C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2)C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C
Tinidazole,CCS(=O)(=O)CCN1C(C)=NC=C1N(=O)=O,Jaundice,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021618/S-000; 021681/S-000; 021682/S-000 Part 01, page:35 PDF 1565k",https://www.pharmapendium.com/browse/fda/Tinidazole/ef8074e8d0653227e6b5ac94398a11e1?reference=35,2004.0,CCS(=O)(=O)CCN1C(C)=NC=C1N(=O)=O
Tiopronin,CC(S)C(=O)NCC(O)=O,Jaundice,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Label 211843/S-001, page:4 PDF 385k",https://www.pharmapendium.com/browse/fda/Tiopronin/715f2a662be9444eb6de5befe412c0bb?reference=4,2019.0,CC(S)C(=O)NCC(O)=O
Tipranavir,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1,Jaundice,Human,-3.0969100130080562,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021814/S-000 Part 02, page:14 PDF 5958k",https://www.pharmapendium.com/browse/fda/Tipranavir/892ba4f96b2adfd7e7df3f8b6fc8a1db?reference=14,2005.0,CCC[C]1(CCC2=CC=CC=C2)CC(O)=C([CH](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1
Tizanidine Hydrochloride,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,Jaundice,Human,-1.5563025007672873,Repeated,Oral,"FDA approval package document: Medical Officer Review 020397, page:10 PDF 728k",https://www.pharmapendium.com/browse/fda/Tizanidine Hydrochloride/fadd8cf1a4115fd6ce090d88629487af?reference=10,1994.0,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
Tolcapone,CC1=CC=C(C=C1)C(=O)C1=CC(O)=C(O)C(=C1)N(=O)=O,Jaundice,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020697 Part 01, page:71 PDF 2767k",https://www.pharmapendium.com/browse/fda/Tolcapone/e50eb2abbcbc16b6e24245e4375e47b5?reference=71,1996.0,CC1=CC=C(C=C1)C(=O)C1=CC(O)=C(O)C(=C1)N(=O)=O
Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,Jaundice,Human,-2.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:65 PDF 422k",https://www.pharmapendium.com/browse/ema/Tolvaptan/833175d74efa2a58b05e32af479e94e3?reference=65,2021.0,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2
Trazodone Hydrochloride,ClC1=CC(=CC=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,Jaundice,Human,-2.574031267727719,Repeated,Oral,"FDA approval package document: Label 022411/S-000, page:12 PDF 1121k",https://www.pharmapendium.com/browse/fda/Trazodone Hydrochloride/a511d30aeae8c87a776cb787b11bb761?reference=12,2010.0,ClC1=CC(=CC=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
Triazolam,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12,Jaundice,Human,-1.3979400086720377,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Triazolam-0057   ---   DOI:10.1136/pgmj.57.673.730   JOURNAL:Postgraduate Medical Journal   PAGES:730   VOLUME:57,http://dx.doi.org/10.1136/pgmj.57.673.730,1981.0,CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12
Trimethadione,CN1C(=O)OC(C)(C)C1=O,Jaundice,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 005856, page:4 PDF 429k",https://www.pharmapendium.com/browse/fda/Trimethadione/16100327bf92589fbc21a628ab4f541a?reference=4,1946.0,CN1C(=O)OC(C)(C)C1=O
Troleandomycin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1OC(C)=O)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(C)=O)N(C)C)[C@@H](C)C[C@@]2(CO2)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]1C,Jaundice,Human,-3.845098040014257,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Therapie. 1982 Jul-Aug; 37(4):443-6. [Therapie]   ---   JOURNAL:Therapie   PAGES:443   VOLUME:37,,1982.0,CO[CH]1C[CH](O[CH](C)[CH]1OC(C)=O)O[CH]1[CH](C)[CH](O[CH]2O[CH](C)C[CH]([CH]2OC(C)=O)N(C)C)[CH](C)C[C]2(CO2)C(=O)[CH](C)[CH](OC(C)=O)[CH](C)[CH](C)OC(=O)[CH]1C
Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/78409/2021; EMEA/H/C/005263/0000, page:115 PDF 7669k",https://www.pharmapendium.com/browse/ema/Tucatinib/9853a892aaf187403450ff694ca2cbcd?reference=115,2020.0,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: Assessment Report EMA/70192/2018; EMEA/H/A-31/1496, page:4 PDF 374k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/c129333ea657fa9e9bb2fdc3911b5801?reference=4,2020.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
Ursodiol,[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])CC[C@]3(C)[C@]([H])(CC[C@@]3([H])[C@]1([H])[C@@H](O)C2)[C@H](C)CCC(O)=O,Jaundice,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020675/S-000 Part 03, page:22 PDF 911k",https://www.pharmapendium.com/browse/fda/Ursodiol/60896b2e7a7aff1e5476fbd99c92f98b?reference=22,1996.0,[H][C]12C[CH](O)CC[C]1(C)[C]1([H])CC[C]3(C)[C]([H])(CC[C]3([H])[C]1([H])[CH](O)C2)[CH](C)CCC(O)=O
Venlafaxine Hydrochloride,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Jaundice,Human,-2.3521825181113627,Repeated,Oral,"FDA approval package document: Label 022104/S-000, page:19 PDF 3066k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/e87ef146efbee14f7cabdd861bd01b9e?reference=19,,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Vigabatrin,NC(CCC(O)=O)C=C,Jaundice,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 06, page:57 PDF 6387k",https://www.pharmapendium.com/browse/fda/Vigabatrin/150f09a447bc03963ea33ba49100971a?reference=57,2009.0,NC(CCC(O)=O)C=C
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Jaundice,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021266/S-000; 021267/S-000 Part 04, page:35 PDF 1582k",https://www.pharmapendium.com/browse/fda/Voriconazole/b91def2fd3ba7fba9e4703146e866659?reference=35,2001.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Zafirlukast,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C,Jaundice,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical Officer Review 020547, page:65 PDF 2594k",https://www.pharmapendium.com/browse/fda/Zafirlukast/2cb7183d95694b6622ca01cb9e9fda48?reference=65,1999.0,COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C
Zalcitabine,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,Jaundice,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 020199 Part 04, page:38 PDF 8974k",https://www.pharmapendium.com/browse/fda/Zalcitabine/1a6c18c41ff32adec49f8c551f2fef99?reference=38,1992.0,NC1=NC(=O)N(C=C1)[CH]1CC[CH](CO)O1
Zidovudine,CC1=CN([C@H]2C[C@H](N=N#N)[C@@H](CO)O2)C(=O)NC1=O,Jaundice,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022294/S-000, page:10 PDF 1706k",https://www.pharmapendium.com/browse/fda/Zidovudine/70ff07f13b40ebc73f6eb329d66c9777?reference=10,2009.0,CC1=CN([CH]2C[CH](N=N#N)[CH](CO)O2)C(=O)NC1=O
Zileuton,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,Jaundice,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020471/S-009, page:10 PDF 1570k",https://www.pharmapendium.com/browse/fda/Zileuton/b0a168b63e38558264aee455efee2c0a?reference=10,2002.0,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
Zinc Acetate,CC([O-])=O,Jaundice,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: Scientific Discussion, page:25 PDF 431k",https://www.pharmapendium.com/browse/ema/Zinc Acetate/22c77179bea14e7701061bfe5f6fc5e9?reference=25,2004.0,CC([O-])=O
Ziprasidone Hydrochloride,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=CC=CC=C12,Jaundice,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020825/S-034 Part 01, page:16 PDF 539k",https://www.pharmapendium.com/browse/fda/Ziprasidone Hydrochloride/2f192022c7405e61acdb244011035ee1?reference=16,2009.0,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=CC=CC=C12
Zomepirac,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1,Jaundice,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018236/S-008, S-009, S-015, S-017, S-018, S-024 Part 01, page:35 PDF 4981k",https://www.pharmapendium.com/browse/fda/Zomepirac/10da7357d7cbbfd7b3b016170e4e470c?reference=35,1983.0,CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
